Novel mRNA vaccine provides full protection against malaria in mice
A new mRNA vaccine based on the malaria circumsporozoite protein was shown to elicit a robust immune response in mice.
List view / Grid view
A new mRNA vaccine based on the malaria circumsporozoite protein was shown to elicit a robust immune response in mice.
Scientists say COVID-19 may activate tuberculosis infection, but stem cell-mediated defence mechanisms could be targeted to develop vaccines.
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
Antibodies produced by B cells against the H1N1 influenza virus can also neutralise other strains, which could be used to developed vaccines.
A new DNA vaccine encoding the SARS-CoV-2 Spike protein has shown promise at protecting mice and hamsters against COVID-19.
Researchers have discovered a cross-reactive coronavirus antibody that could aid in the development of a broad-acting vaccine or treatment.
Using nanoparticle liposomes, researchers have developed an experimental flu vaccine that has shown success in pre-clinical studies.
A new conjugate vaccine has shown promise at protecting mice against the effects of cytokines associated with asthma.
Researchers have designed a new nanoparticle-based vaccine against Ebola that has shown promise in mice and rabbits.
A new vaccine has shown promise at protecting monkeys and mice from COVID-19, its variants and other coronaviruses.
Exosomes containing salmonella antigens were administered to the mice, enabling the models to develop antibodies against the bacteria.
Researchers have developed a vaccine using stem cells that protected mice injected with pancreatic cancer cells from developing tumours.
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.
A summit will be held between the UK and CEPI to raise funds for vaccine research and development in a bid to avert future pandemics.
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.